Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GAR1 ribonucleoprotein is a conserved, glycine- and arginine-rich nucleolar protein that forms part of the **H/ACA snoRNP complex**, which is essential for **rRNA pseudouridylation** and **ribosome biogenesis** in eukaryotic cells[3][4][7][1]. It facilitates substrate RNA placement, enhances the catalytic activity of Cbf5 (the pseudouridine synthase), and is necessary for the correct processing of pre-rRNA substrate and 18S rRNA formation[2][5][1]. GAR1 associates with other core proteins (NAP57/dyskerin/Cbf5, NHP2, and NOP10), and plays roles in telomerase holoenzyme assembly and function, with essentiality reflected by impaired cell growth in its absence[1][3][7][8]. GAR1's dysfunction is mapped to diseases involving ribosomal defects and telomerase activity, including Fanconi anemia and spinal muscular atrophy[3]. No known drugs interact directly with GAR1, nor is it a clinical biomarker or therapeutic target in current data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GAR1 ribonucleoprotein (GAR1).